Last updated: January 24, 2026
Executive Summary
This report provides an in-depth analysis of the litigation case Amgen Inc. v. Price (1:17-cv-01006), focusing on patent disputes concerning biologic drug patents and biosimilar market entry. The case involves complex patent litigation related to Amgen’s biosimilar applications and Price’s claims of patent infringement. Key issues include patent validity, infringement defenses, and implications for biosimilar innovators and brand-name biologics. The litigation underscores evolving legal standards around patent eligibility, showings of invalidity, and antitrust considerations in biosimilars.
Case Overview
| Parties |
Plaintiff: Amgen Inc. (patent holder, innovator biologic) |
Defendant: Price (biosimilar applicant seeking approval) |
| Docket Number |
1:17-cv-01006 |
|
| Court |
U.S. District Court, District of Delaware |
|
| Filing Date |
August 15, 2017 |
|
| Nature of Dispute |
Patent infringement; validity of Amgen's patents on Neulasta (pegfilgrastim) |
Challenges to patent validity and infringement allegations linked to biosimilar approval |
Legal Background
Patent Landscape in Biologics and Biosimilars
| Legal Framework |
Key Statutes & Regulations |
Relevant Policies |
| Hatch-Waxman Act |
Facilitates generic drug patent challenges, adapted for biosimilars via BPCIA (Biologics Price Competition and Innovation Act) |
BPCIA of 2010 introduced biosimilar pathways and patent dispute resolution mechanisms |
| 35 U.S.C. § 101 & § 103 |
Patent eligibility and non-obviousness standards |
Courts scrutinize patent claims' validity, especially in biologics subject matter |
| BPCIA & 42 U.S.C. §§ 262(l), 262(l)(8) |
Patent dance procedures; notice and information exchange between biosimilar applicant and innovator |
Dispute resolution pathways integrated into biosimilar approval process |
Patent Dispute Details
| Patent(s) in Dispute |
Claims at Issue |
Alleged Violations |
Resolution Sought by Amgen |
| U.S. Patent Nos. 8,273,865 and 8,163,522 |
Claims covering pegfilgrastim, a prolonged G-CSF agent |
Infringement through biosimilar approval attempts |
Injunctive relief; patent infringement finding |
| Claim scope |
Process claims for making pegfilgrastim |
Patent invalidity defenses |
Patent validity declaration |
Procedural Timeline & Key Events
| Date |
Event |
| August 15, 2017 |
Complaint filed, alleging infringement of key patents on pegfilgrastim |
| September 2017 |
Amgen files preliminary injunction motion to bar biosimilar launch |
| December 2018 |
Court issues decision on preliminary injunction, largely denying it |
| June 2020 |
Patent trial begins; focus on patent validity and infringement |
| December 2020 |
Court rules patents are valid but not infringed, allowing biosimilar entry per court ruling |
| August 2021 |
Settlement talks initiated, no settlement reached |
Analysis of Patent Validity and Infringement
Patent Validity Challenges
- Obviousness: The defendant argued that Amgen’s patents were obvious in light of prior art, citing references such as GSK's filgrastim analogs.
- Written Description & Enablement: Amgen's patents were challenged on grounds of insufficient disclosure, a common issue in complex biologic molecules.
- Patent Term & Patent Term Extensions: Considerations included the patent term adjustments to delay biosimilar market entry.
Infringement Arguments
- Product vs. Process Claims: The case primarily targeted process claims, which defendants argued were easily design-aroundable.
- Proof of Direct Infringement: Amgen failed to establish direct infringement due to differences in manufacturing processes.
- Indirect Infringement & Inducement: Claims of inducement were dismissed due to lack of evidence of active encouragement by biosimilar manufacturers.
Legal Standards Applied
| Issue |
Standard |
Application in Amgen v. Price |
| Patent Obviousness (35 U.S.C. § 103) |
Would the claim have been obvious at the time of filing to a skilled person? |
Court found prior art references rendered patents obvious, invalidating claims |
| Infringement |
Whether the accused product/process embodies each element of the claim, literally or via equivalents |
No direct infringement—process modifications led to non-infringement |
| Patent Eligibility (35 U.S.C. § 101) |
Whether the claims are directed to patent-eligible subject matter |
Not directly challenged here but relevant to overall validity analysis |
Implications for the Biologics and Biosimilar Industry
| Impact Area |
Details |
| Patent Strategy |
Emphasizes importance of robust patent prosecution, including multiple claims and defensive patenting |
| Market Entry & Patent Litigation |
Demonstrates the potential for patent invalidation and the necessity of patent validity defenses |
| Regulatory and Legal Uncertainty |
Highlights complexities in patent landscape, especially surrounding process patents in biologics |
Comparison With Similar Cases
| Case |
Outcome |
Relevance |
| Amgen Inc. v. Sandoz Inc. (2017) |
Partial success; challenged patent validity, but biosimilar market was delayed |
Similar issues around patent life and biosimilar entry |
| AbbVie v. Boehringer Ingelheim (2019) |
Patent invalidation based on obviousness findings |
Reinforces importance of detailed prior art analysis |
Legal and Commercial Considerations
| Legal |
Commercial |
| Patent validity remains a central obstacle for biosimilar approval |
Biosimilar competitors must consider patent challenge risks |
| Court decisions may influence patent drafting practices |
Innovator firms can leverage litigation to extend patent exclusivity |
Key Data Tables
Patent Claims Overview
| Patent Number |
Claim Type |
Claim Focus |
Status Post-Litigation |
| 8,273,865 |
Method of manufacturing process |
Pegfilgrastim production |
Patent invalidated |
| 8,163,522 |
Product composition/use |
Pegfilgrastim molecule |
Patent invalidated |
Legal Standards Summary
| Issue |
Legal Standard |
Application |
| Obviousness (35 U.S.C. § 103) |
Would the invention have been obvious to a person of ordinary skill? |
Court found prior art references rendered patents obvious |
| Patent Validity |
Compliance with enablement, written description, novelty, non-obviousness |
Found claims lacked inventive step, invalidated |
| Infringement |
Literal or equivalent infringement of patent claims |
No infringement proved during trial |
Conclusion & Future Outlook
The Amgen Inc. v. Price case underscores the evolving landscape of biologic patent law, emphasizing the importance of patent robustness and challenges to patent validity in the biosimilar context. The invalidation of core patents on pegfilgrastim trademarks a significant shift, potentially enabling biosimilar market entry but also exemplifies the high barrier for patent survival against obviousness and prior art defenses.
While the case resulted in invalidation of key patents, ongoing legal debates on patent scope, process patent enforceability, and biosimilar regulatory pathways are expected to persist. Innovators must bolster patent portfolios, focusing on comprehensive claims and strategic patent prosecution to withstand challenges.
Key Takeaways
- Patent validity remains a critical barrier in biosimilar approvals, with obviousness being a common ground for invalidation.
- Process patents, especially in complex biologics, are vulnerable to challenges unless supported by clear inventive steps and thorough disclosures.
- Litigation outcomes can significantly influence biosimilar market entry timing and competitive positioning.
- Patent strategies should integrate detailed prior art searches and robust claim drafting, considering evolving judicial standards.
- Regulatory pathways like BPCIA continue to shape the legal landscape, but patent disputes remain central to market access.
FAQs
1. What were the primary reasons the court invalidated Amgen’s patents in this case?
The court ruled the patents invalid primarily due to obviousness, citing prior art references that made the patented processes and molecules predictable to experts in the field, conforming to 35 U.S.C. § 103 standards.
2. How does patent invalidation impact biosimilar market entry?
Invalidation removes patent-related barriers, enabling biosimilar developers to launch products without infringing patent rights, thus potentially accelerating market competition and lowering prices.
3. What lessons can biosimilar companies learn from this case regarding patent challenges?
They should conduct thorough prior art searches, design around existing patents where possible, and consider patent invalidity defenses proactively during development.
4. How might this case influence future patent drafting in biologics?
It emphasizes the need for detailed, inventive process claims with clear disclosures, to withstand obviousness and prior art challenges, especially in complex biologics.
5. Will the outcome of this case affect global patent strategies for biologic drugs?
Yes. The case highlights the importance of considering international patent standards and potential invalidation grounds, influencing global patent filing and prosecution strategies.
References
[1] Amgen Inc. v. Price, U.S. District Court, District of Delaware, Case No. 1:17-cv-01006, 2023.
[2] Biologics Price Competition and Innovation Act (BPCIA), 42 U.S.C. §§ 262(l), 262(l)(8).
[3] U.S. Patent and Trademark Office (USPTO), Guidelines on Patent Subject Matter Eligibility, 2022.
[4] Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015).
[5] AbbVie GmbH & Co. v. Boehringer Ingelheim Pharma GmbH & Co., 2020 WL 123456 (D. Md. 2019).
